SPY335.57+1.00 0.30%
DIA278.14+3.52 1.28%
IXIC10,968.36-42.63 -0.39%

Raymond James Maintains Outperform on Amedisys, Raises Price Target to $255

Raymond James maintains Amedisys (NASDAQ:AMED) with a Outperform and raises the price target from $210 to $255.

Benzinga · -
Raymond James maintains Amedisys (NASDAQ: AMED) with a Outperform and raises the price target from $210 to $255.